Dr. Michael Cecchini, MD

Medicare patients and services

Medicare patients, 2024

122

Services billed

379

Patients’ average age

71

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 33 payments worth $21,760 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Connecticut →

Industry-funded research

Named as a principal investigator on 32 industry-funded studies in 2025, from 13 companies. The companies reported $3,033,493 in research payments for these studies, mostly to the institutions running them.

• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
  AbbVie Inc. · Active, not recruiting · NCT05029882
• A Study of BG-C477 in Participants With Advanced Solid Tumors
  Beone Medicines USA, Inc. · Recruiting · NCT06596473
• A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
  Beigene, Ltd. · Recruiting · NCT05981703
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
  Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249
• A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
  AbbVie Inc. · Active, not recruiting · NCT06614192
• A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
  Ipsen Pharma Sas · Active, not recruiting · NCT06305247
• A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
  Janssen Research & Development, LLC
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
  AbbVie Inc. · Recruiting · NCT06820463
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
  AbbVie Inc. · Active, not recruiting · NCT06107413
• A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
  Beone Medicines USA, Inc. · Recruiting · NCT06625593

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in New Haven

• Jennifer A. Afranie-sakyi, MD
• Luis E. Aguirre, MD
• Ash Alpert
• Matthew Austin
• Jan Philipp Bewersdorf, MD
• Prajwal C. Boddu, M.D.
• Gregory A. Breuer, MD, PHD
• Emily Collier, MD